EnviroTech :: R&D
Denmark's Novo acquires Xellia Pharmaceuticals in $700-million deal
9:09 AM MDT | May 22, 2013 | Francinia Protti-Alvarez
Novo A/S (Hellerup, Denmark), parent of pharmaceutical firm Novo Nordisk (Bagsvaerd, Denmark), has acquired Xellia Pharmaceuticals (Oslo) from private equity firm 3i (London) for an enterprise value of $700 million, 3i and Novo have announced. The company 3i says it reaped a 2.3-times return on the original $395-million investment made in 2008. The closing of the transaction will be subject to relevant competition law approvals and is expected to take place during the third quarter of 2013. "Xellia strongly complements our portfolio of significant...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee